GFAP and Cognitive impairment: More importantly, hyperforin treatment significantly reduced Aβ deposition (Supplemental Figure 12A), GFAP expression (Supplemental Figure 12B), levels of IFN-γ, IL-1β, IL-6, and TNFα (Supplemental Figure 12C), and improved performance in behavioral tests (Supplemental Figure 13, A–G), suggesting reversal of cognitive deficits.